Primary HIV infection: Early diagnosis and treatment are critical to outcome

Postgraduate Medicine

Volumn 102, Issue 4, 1997, Pages 143-151

  Schacker, Timothy ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Fairview University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; PROPHYLAXIS; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY; VACCINATION;

EID: 0030720878     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.10.333     Document Type: Conference Paper

References (40)

1. Winkelstein W Jr, Samuel M, Padian NS, et al. The San Francisco Men's Health Study: III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-86. Am J Public Health 1987;77(6):685-9
2. Winkelstein W Jr, Wiley JA, Padian NS, et al. The San Francisco Men's Health Study: continued decline in HIV seroconversion rates among homosexual/bisexual men. Am J Public Health 1988;78(11):1472-4
3. van Griensven GJ, de Vroome EM, Goudsmit J, et al. Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. BMJ 1989;298(6668):218-21
4. Plummer FA, Simonsen JN, Cameron DW, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991;163(2):233-9
5. Stamm WE, Handsfield HH, Rompalo AM, et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988;260(10):1429-33
6. Telzak EE, Chiasson MA, Bevier PJ, et al. HIV-1 seroconversion in patients with and without genital ulcer disease: a prospective study. Ann Intern Med 1993;119(12):1181-6
7. Nelson KE, Vlahov D, Cohn S, et al. Sexually transmitted diseases in a population of intravenous drug users: association with seropositivity to the human immunodeficiency virus (HIV). J Infect Dis 1991;164(3):457-63
8. Darrow WW, Echenberg DF, Jaffe HW, et al. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am J Public Health 1987;77(4):479-83
9. Centers for Disease Control and Prevention. Number of sex partners and potential risk of sexual exposure to human immunodeficiency virus. MMWR 1988;37(37):565-8
10. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126(2):310-8
11. Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125(4):257-64 [Erratum, Ann Intern Med 1997;126(2):174]
12. Carlin E, Miller L, Boag F. The hazards of oral sex. (Letter) Sex Transm Dis 1994;21(4):241-2
13. Baba TW, Trichel AM, An L, et al. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science 1996;272(5267):1486-9
14. Lifson AR, O'Malley PM, Hessol NA, et al. HIV seroconversion in two homosexual men after receptive oral intercourse with ejaculation: implications for counseling concerning safe sexual practices. Am J Public Health 1990;80(12):1509-11
15. Spitzer PG, Weiner NJ. Transmission of HIV infection from a woman to a man by oral sex. (Letter) N Engl J Med 1989;320(4):251
16. Sinicco A, Fora R, Sciandra M, et al. Risk of developing AIDS after primary acute HIV-1 infection. J Acquir Immune Defic Syndr 1993;6(6):575-81
17. Kinloch-de Loes S, de Saussure P, Saurat JH, et al. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis 1993;17(1):59-65
18. Phair J, Jacobson L, Detels R, et al. Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1992;5(5):490-6
19. Keet IP, Krijnen P, Koot M, et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993;7(1):51-7
20. Lindback S, Brostrom C, Karlsson A, et al. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4+ count below 200 × 10(6)/1, AIDS, and death from AIDS? BMJ 1994;309(6968):1535-7
21. Vento S, Di Perri G, Garofano T, et al. Pneumocystis carinii pneumonia during primary HIV-1 infection. Lancet 1993;342(8862): 24-5
22. Cooper DA. Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus. J Infect Dis 1988;157(5):889-96
23. Gorham ED. CD4 lymphocyte counts within 24 months of human immunodeficiency virus seroconversion: findings in the US Navy and Marine Corps. The Navy Retroviral Working Group. Arch Intern Med 1993;153(7):869-76
24. Henrard DR, Daar E, Farzadegan H, et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9(3):305-10
25. Baumberger C, Kinloch-de Loes S, Yerly S, et al. High levels of circulating RNA in patients with symptomatic HIV-1 infection. AIDS 1993;7(Suppl 2):S59-64
26. Daar ES, Moudgil T, Meyer RD, et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324(14):961-4
27. Piatak M Jr, Yang LC, Luk KC, et al. Viral dynamics in primary HIV-1 infection. (Letter) Lancet 1993;341(8852):1099
28. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324(14):954-60
29. Clark SJ, Shaw GM. The acute retroviral syndrome and the pathogenesis of HIV-1 infection. Semin Immunol 1993;5(3):149-55
30. Le Grand R, Clayette P, Noack O, et al. An animal model for antilentiviral therapy: effect of zidovudine on viral load during acute infection after exposure of macaques to simian immunodeficiency virus. AIDS Res Hum Retroviruses 1994;10(10):1279-87
31. Gerberding JL. Prophylaxis for occupational exposure to HIV. Ann Intern Med 1996;125(6):497-501
32. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45(22):468-80
33. Lange JM, Boucher CA, Hollak CE, et al. Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med 1990;322(19):1375-7
34. Looke DF, Grove DI. Failed prophylactic zidovudine after needlestick injury. (Letter) Lancet 1990;335(8700):1280
35. Durand E, Le Jeunne C, Hugues FC. Failure of prophylactic zidovudine after suicidal self-inoculation of HIV-infected blood. (Letter) N Engl J Med 1991;324(15):1062
36. Jones PD. HIV transmission by stabbing despite zidovudine prophylaxis. (Letter) Lancet 1991;338(8771):884
37. Resisting the temptation. (Editorial) Lancet 1993;342(8869):448
38. Tindall B, Gaines H, Imrie A, et al. Zidovudine in the management of primary HIV-1 infection. AIDS 1991;5(5):477-84
39. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333(7):408-13 [Erratum, N Engl J Med 1995;333(20):1367]
40. Perrin L, Rakik A, Yerly S, et al. Combined therapy with zidovudine and L-697,661 in primary HIV infection. AIDS 1996; 10(11):1233-7